Chief Research Officer, Awakn Life Sciences
Prof. Nutt is Chief Research Officer at Awakn Life
Sciences, a biotechnology company with clinical
operations, developing and delivering psychedelic
therapeutics (medicines and therapies) to better treat
He is a psychiatrist and the Edmund J. Safra Professor
of Neuropsychopharmacology in the Division of Brain
Science, Dept of Medicine, Imperial College London,
where he uses a range of brain imaging techniques to
explore the causes of addiction and other psychiatric
disorders and to search for new treatments. He is also director of the Neuropsychopharmacology Unit in the Division of Brain Sciences. He completed his medical training at Guy’s Hospital London in neurology to magnetic resonance cholangiopancreatography (MRCP), before training in psychiatry in
Oxford and continuing there as a lecturer and a Wellcome Senior Fellow in Psychiatry. In 1988 he set up the Psychopharmacology Unit in Bristol University, an interdisciplinary research group spanning the departments of Psychiatry and Pharmacology before moving to Imperial College London in December 2008, where he leads a similar group with a particular focus on brain imaging.
Prof. Nutt is President of the European Brain Council and Founding Chair of Drug Science. Previously, he was President of the European College of Neuropsychopharmacology, the British
Neuroscience Association and the British Association of Psychopharmacology. In addition, he is aFellow of the Royal Colleges of Physicians and of Psychiatrists and a Fellow of the Academy of Medical Sciences. He has published over 500 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 34 books.
He broadcasts widely to the general public both on radio and television. In 2010, The Times Eureka science magazine voted him one of the 100 most important figures in British Science and in 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.